Message from the CEO
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development facility in Notting Hill and we are busy completing the preclinical studies for our lead iNK product for treating ovarian cancer. The follow-on product pipeline is revving up with new CAR target candidates, additional gene […]